X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
evacetrapib (57) 57
index medicus (42) 42
humans (33) 33
anacetrapib (27) 27
cholesterol ester transfer proteins - antagonists & inhibitors (23) 23
coronary-heart-disease (23) 23
torcetrapib (23) 23
dalcetrapib (20) 20
pharmacology & pharmacy (19) 19
cholesteryl ester transfer protein (17) 17
ester transfer protein (17) 17
high-risk (16) 16
cardiac & cardiovascular systems (15) 15
female (15) 15
hdl (14) 14
high-density-lipoprotein (14) 14
anticholesteremic agents - therapeutic use (13) 13
male (13) 13
cholesterol, hdl - blood (12) 12
lipids (12) 12
cholesterol, ldl - blood (11) 11
middle aged (11) 11
animals (10) 10
cardiovascular diseases - prevention & control (10) 10
cholesterol (10) 10
hdl cholesterol (10) 10
peripheral vascular disease (10) 10
statins (10) 10
anticholesteremic agents - pharmacology (9) 9
cetp (9) 9
density-lipoprotein cholesterol (9) 9
benzodiazepines - adverse effects (8) 8
benzodiazepines - pharmacology (8) 8
ldl cholesterol (8) 8
risk factors (8) 8
safety (8) 8
adult (7) 7
aged (7) 7
benzodiazepines - administration & dosage (7) 7
benzodiazepines - therapeutic use (7) 7
blood-pressure (7) 7
cardiovascular disease (7) 7
cholesteryl ester transfer protein inhibitor (7) 7
combination (7) 7
dyslipidemias - drug therapy (7) 7
hdl-cholesterol (7) 7
hypercholesterolemia (7) 7
inhibitor evacetrapib (7) 7
randomized controlled-trial (7) 7
treatment outcome (7) 7
analysis (6) 6
anticholesteremic agents - adverse effects (6) 6
apolipoproteins (6) 6
atherosclerosis (6) 6
cardiovascular diseases (6) 6
cholesterol ester transfer proteins - metabolism (6) 6
cholesterol, hdl - drug effects (6) 6
double-blind method (6) 6
dyslipidemias - blood (6) 6
efflux capacity (6) 6
low density lipoproteins (6) 6
research (6) 6
benzodiazepines - pharmacokinetics (5) 5
blood lipids (5) 5
cardiovascular (5) 5
cardiovascular diseases - drug therapy (5) 5
coronary artery disease (5) 5
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (5) 5
hypercholesterolemia - drug therapy (5) 5
lipoproteins (5) 5
usage (5) 5
cardiology (4) 4
cardiovascular events (4) 4
cetp inhibitor (4) 4
clinical trials (4) 4
disease (4) 4
dosage and administration (4) 4
hdl-c (4) 4
high density lipoprotein (4) 4
high-density lipoprotein (4) 4
inhibitor (4) 4
ldl-cholesterol (4) 4
low density lipoprotein (4) 4
low-density lipoprotein cholesterol (4) 4
medicine & public health (4) 4
monotherapy (4) 4
pharmacokinetics (4) 4
reverse cholesterol transport (4) 4
triglycerides (4) 4
type-2 diabetes-mellitus (4) 4
young adult (4) 4
alirocumab (3) 3
anticholesteremic agents - administration & dosage (3) 3
anticholesteremic agents - pharmacokinetics (3) 3
benzodiazepines - toxicity (3) 3
betrixaban (3) 3
biochemistry & molecular biology (3) 3
biomarkers - blood (3) 3
cardiovascular clinical outcomes (3) 3
cardiovascular-disease (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation Journal, ISSN 1346-9843, 2017
Background:Inhibition of cholesteryl ester transfer protein by evacetrapib when added to atorvastatin may provide an additional treatment option for patients... 
Low-density lipoprotein | Hypercholesterolemia | Evacetrapib | High-density lipoprotein | Cholesteryl ester transfer protein inhibitor
Journal Article
Circulation Journal, ISSN 1346-9843, 2017
Background:Inhibition of cholesteryl ester transfer protein with evacetrapib may provide an additional treatment option for patients who do not reach their... 
Hypercholesterolemia | Evacetrapib | High-density lipoprotein cholesterol | Cholesteryl ester transfer protein inhibitor | Low-density lipoprotein cholesterol
Journal Article
JAMA, ISSN 0098-7484, 09/2017, Volume 318, Issue 10, pp. 947 - 956
IMPORTANCE: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular... 
MEDICINE, GENERAL & INTERNAL | LDL-CHOLESTEROL | METAANALYSIS | ESTER TRANSFER PROTEIN | GENOME-WIDE | RANDOMIZED CONTROLLED-TRIAL | MENDELIAN RANDOMIZATION | CORONARY-HEART-DISEASE | DISCORDANCE | VASCULAR-DISEASE | EVACETRAPIB | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Hypercholesterolemia - blood | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Apolipoproteins B - blood | Cardiovascular Diseases - genetics | Hypercholesterolemia - drug therapy | Genetic Variation | Anticholesteremic Agents - therapeutic use | Cholesterol Ester Transfer Proteins - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mendelian Randomization Analysis | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Female | Hypercholesterolemia - genetics | Hydroxymethylglutaryl CoA Reductases - genetics | Proteolipids | Lipoproteins | Usage | Genetic variation | Analysis | Research | Blood lipoproteins | Statins | Heart | Lipoproteins (low density) | Cardiovascular disease | CETP gene | Risk factors | Apolipoprotein B | Reduction | Genetics | Attenuation | Heart diseases | Lipoproteins (high density) | Discordance | Health risks | Exposure | Apolipoproteins | Low density lipoprotein | Coronary artery disease | Cholesterol | Cholesteryl ester transfer protein | Genetic variance | Inhibitors | Cardiovascular diseases | Reductase | Index Medicus | Abridged Index Medicus | Online First | Original Investigation
Journal Article
Circulation, ISSN 0009-7322, 03/2018, Volume 137, Issue 10, pp. 1011 - 1014
Assessing drug safety and efficacy is costly, and many promising candidates can present unwanted side effects. Can new developments in proteomic biomarkers... 
Drugs | Biomarkers | Clinical trials | Editorials | Proteomics | CARDIAC & CARDIOVASCULAR SYSTEMS | proteomics | drugs | biomarkers | DISEASE | TORCETRAPIB | PERIPHERAL VASCULAR DISEASE | clinical trials | Quinolines | Early Diagnosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Tetrahedron Letters, ISSN 0040-4039, 11/2013, Volume 54, Issue 48, pp. 6587 - 6591
The identification and development of an aldehyde–bisulfite adduct as an isolable starting material in the synthesis of the CETP inhibitor Evacetrapib are... 
Rosenmund reduction | Aldehyde–bisulfite adduct | Solid state properties | Evacetrapib | Aldehyde-bisulfite adduct | CHEMISTRY, ORGANIC | INHIBITOR | DERIVATIVES | REDUCTIVE AMINATION | Sulfites
Journal Article
Journal of Chromatography A, ISSN 0021-9673, 10/2014, Volume 1363, pp. 183 - 190
Using HPLC chiral separation screening, various columns representing the polysaccharide, macrocyclic antibiotic and brush classes were assessed in multiple... 
Pirkle | Evacetrapib | Brush | Chiral | Whelk O-1 | Enantiomer | FLUID CHROMATOGRAPHY | CHEMISTRY, ANALYTICAL | DESIGN | BIOCHEMICAL RESEARCH METHODS | NAPROXEN | HPLC | Enantiomers | High performance liquid chromatography | Methods
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 04/2018, Volume 19, Issue 6, pp. 611 - 615
Introduction: The actions of the cholesteryl ester transfer protein (CETP) inhibitors (torcetrapib, dalcetrapib and evacetrapib) include increasing... 
Anacetrapib | cardiovascular clinical outcomes | cholesteryl ester transfer protein (CETP) | evacetrapib | LDL cholesterol | REVEAL | torcetrapib | dalcetrapib | HDL cholesterol | SAFETY | DENSITY-LIPOPROTEIN CHOLESTEROL | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | Index Medicus
Journal Article
Journal of Clinical Lipidology, ISSN 1933-2874, 01/2018, Volume 12, Issue 1, pp. 110 - 115
Hyperalphalipoproteinemia (HALP) is inversely correlated with coronary heart disease (CHD) although genetic variants associated with high serum levels of... 
HDL-C | cardioprotection | Hyperalpha | HALP | CAD | Exome sequencing | VARIANT | DENSITY-LIPOPROTEIN CHOLESTEROL | HIGH-RISK | PHARMACOLOGY & PHARMACY | HDL CHOLESTEROL | CORONARY-HEART-DISEASE | EVACETRAPIB
Journal Article
DIABETES & VASCULAR DISEASE RESEARCH, ISSN 1479-1641, 03/2019, Volume 16, Issue 2, pp. 171 - 177
Background: Despite optimal treatment, type II diabetes mellitus remains associated with an increased risk for future cardiovascular events. We sought to... 
MORTALITY | revascularization | MYOCARDIAL-INFARCTION | Plasma insulin | ACTIVATOR INHIBITOR TYPE-1 | HYPERINSULINEMIA | diabetes mellitus | PIOGLITAZONE | PLASMINOGEN-ACTIVATOR | ENDOCRINOLOGY & METABOLISM | RESISTANCE | PERIPHERAL VASCULAR DISEASE | OUTCOMES | major adverse cardiovascular events | CORONARY-HEART-DISEASE | EVACETRAPIB
Journal Article
CIRCULATION-GENOMIC AND PRECISION MEDICINE, ISSN 2574-8300, 05/2018, Volume 11, Issue 5, pp. e002034 - e002034
BACKGROUND: We aimed to identify independent genetic determinants of circulating CETP (cholesteryl ester transfer protein) to assess causal effects of... 
coronary artery disease | lipids | CARDIAC & CARDIOVASCULAR SYSTEMS | VARIANTS | cardiovascular diseases | HIGH-DENSITY-LIPOPROTEIN | HEART | POLYMORPHISMS | GENE | HIGH-RISK | MASS | GENETICS & HEREDITY | EXPRESSION | EVACETRAPIB | Genome-wide association studies | Usage | Care and treatment | Lipid metabolism | Research | Coronary heart disease | Risk factors | Index Medicus
Journal Article
EXPERT OPINION ON PHARMACOTHERAPY, ISSN 1465-6566, 2017, Volume 18, Issue 14, pp. 1439 - 1442
Introduction: Increasing high-density lipoprotein(HDL) cholesterol levels predict improved cardiovascular outcomes. However, inhibiting cholesteryl ester... 
GEMFIBROZIL | cardiovascular clinical outcomes | anacetrapib | cholesteryl ester transfer protein (CETP) | evacetrapib | dalcetrapib | HDL cholesterol | DENSITY-LIPOPROTEIN CHOLESTEROL | ACCELERATE | REDUCTION | HIGH-RISK | MEN | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | torcetrapib
Journal Article
Atherosclerosis, ISSN 0021-9150, 2017, Volume 257, pp. 186 - 194
Abstract Background and aims High-density lipoprotein cholesterol (HDL-C) is inversely related to cardiovascular risk. HDL-C raising ester transfer protein... 
Cardiovascular | Endothelial dysfunction | CETP | HDL-Cholesterol | Hyperlipidemia | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | RANDOMIZED CLINICAL-TRIAL | BLOOD-PRESSURE | HIGH-DENSITY-LIPOPROTEIN | REVERSE CHOLESTEROL TRANSPORT | HIGH-RISK | ESTER-TRANSFER PROTEIN | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | INHIBITOR EVACETRAPIB | CORONARY-HEART-DISEASE | Aryldialkylphosphatase - blood | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Dyslipidemias - genetics | Up-Regulation | Reactive Oxygen Species - metabolism | Humans | Endothelium, Vascular - drug effects | Dyslipidemias - blood | Oxazolidinones - toxicity | Cholesterol Ester Transfer Proteins - genetics | Diet, High-Fat | Female | Disease Models, Animal | Anticholesteremic Agents - toxicity | Dyslipidemias - drug therapy | Genetic Predisposition to Disease | Benzodiazepines - pharmacology | Endothelium, Vascular - physiopathology | Mice, Transgenic | Biomarkers - blood | Apolipoprotein E3 - genetics | Phenotype | Animals | Benzodiazepines - toxicity | Endothelium, Vascular - metabolism | Oxazolidinones - pharmacology | Triglycerides - blood | Cholesterol, HDL - blood | Vasodilation - drug effects | Cholesterol Ester Transfer Proteins - metabolism | Anticholesteremic Agents - pharmacology | Dyslipidemias - physiopathology | Therapeutics | Triglycerides | Genetic engineering | Blood lipids | Cardiology | Homeopathy | Materia medica and therapeutics | Endothelium | Dilatation | Analysis | Blood vessels | Acetylcholine | Index Medicus
Journal Article